Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-θ-d-Arabinofuranosylcytosine

Cancer Research

Volumn 50, Issue 17, 1990, Pages 5318-5327

  Greco, William R ^a,b   Park, Hyoung Sook ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; DRUG POTENTIATION; LEUKEMIA L 1210; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ANIMAL; CISPLATIN; CYTARABINE; DRUG SYNERGISM; KINETICS; LEUKEMIA L1210; MATHEMATICS; MICE; MODELS, THEORETICAL; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0025113618     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Loewe, S. Die Quantitation Probleme der Pharmakologie. Ergebn. Physiol., 27:47–187, 1928.
2. Chou, T.-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul., 22:27–55, 1984.
3. Chou, T.-C., and Talalay, P. Generalized equations for the analysis of inhibitions of Michael is-Men ten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem., 115:207–216, 1981.
4. Berenbaum, M. C. The expected effect of a combination of agents: the general solution. J. Theor. Biol., 114:413–431, 1985.
5. Hewlett, P. S., and Plackett, R. L. The Interpretation of Quantal Responses in Biology, London: E. Arnold UK, 1979.
6. Hewlett, P. S. Measurement of the potencies of drug mixtures. Biometrics, 25:477–487, 1969.
7. Finney, D. J. Probit Analysis, Ed. 2. Cambridge, England: Cambridge University Press, 1952.
8. McCullagh, P., and Neider, J. A. Generalized Linear Models. London: Chapman and Hall, Ltd., 1983.
9. Carter, W. H., Jr., Wampler, G. L., and Stablein, D. M. Regression Analysis of Survival Dato in Cancer Chemotherapy, New York: Marcel Dekker, Inc., 1983.
10. Syracuse, K. C., and Greco, W. R. Comparison between the method of Chou and Talalay and a new method for the assessment of the combined effects of drugs: a Monte-Carlo simulation study. Proc. Biopharm. Sect. Am. Stat Assoc., 127–132, 1986.
11. Greco, W. R., and Lawrence, D. L. Assessment of the degree of drug interaction where the response variable is discrete. Proc. Biopharm. Sect. Am. Stat Assoc. 226–231, 1988.
12. Greco, W. R. The assessment of synergism, antagonism, additivity, potentiation and inhibition: a unified optimal approach. Pharmacologist, 29: 161, 1987.
13. Greco, W. R. The assessment of synergism, antagonism, and additivity: a unified optimal approach. Proc. Am. Assoc. Cancer Res., 28:426, 1987.
14. Park, H. S., Rustum, Y. M., and Greco, W. R. Quantitation of the dynamics of the synergistic interaction between cisplatin and arabinosylcytosine on the growth inhibition of murine L1210 leukemia in vitro. Proc. Am. Assoc. Cancer Res., 29:480, 1988.
15. Chou, J., and Chou, T.-C. Dose Effect Analysis with Microcomputers. Amsterdam: Elsevier Science Publishers BV, 1985.
16. Hill, A. V. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. (Lond.), 40: iv–vii, 1910.
17. Holford, N. H. G., and Sheiner, L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet., 6:429–453, 1981.
18. Waud, D. R., and Parker, R. B. Pharmacological estimation of drug-receptor dissociation constants, statistical evaluation. II. Competitive antagonists. J. Pharmacol. Exp. Ther., 117:13–24, 1971.
19. Waud, D. R., and Waud, B. E. Heuristic and practical graphing of dose-response relationships. Trends Pharmacol. Sci., 6:26–30, 1985.
20. Marquardt, D. W. An algorithm for least squares estimation of nonlinear parameters. J. Soc. Ind. Appl. Math., 11:431–441, 1963.
21. Nash, J. C. Compact Numerical Methods for Computers: Linear Algebra and Function Minimisation, pp. 136–137. New York: John Wiley & Sons, Inc., 1979.
22. Thisted, R. A. Elements of Statistical Computing, p. 170, Algorithm 4.2.5. New York: Chapman and Hall, Ltd., 1988.
23. SAS Institute, Inc. SAS/STAT Guide for Personal Computers, Version 6 Ed. Cary, NC: SAS Institute, Inc., 1987.
24. Dixon, W. J., Brown, M. B., Engelman, L., Hill, M. A., and Jennrich, R. I. (eds.) BMDP Statistical Software Manual, Berkeley, CA: University of California Press, 1988.
25. Statistical Consultants Inc. PCNONLIN and NONLIN84 software for the statistical analysis of nonlinear models. Am. Statistician, 40:52, 1986.
26. Webb, J. L. Effect of more than one inhibitor. In: Enzyme and Metabolic Inhibitors, Vol. 1, pp. 66–79,488–512. New York: Academic Press, 1963.
27. Elion, G. B., Singer, S., and Hitchings, G. H. Antagonists of nucleic acid and derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem., 208:477–488, 1954.
28. Berenbaum, M. C. Criteria for analysing interactions between biologically active agents. Adv. Cancer Res., 35:269–335, 1981.
29. Bates, D. M., and Watts, D. G. Nonlinear Regression Analysis and Its Applications, p. 91. New York: John Wiley & Sons, Inc., 1988.
30. Landaw, E. M. Optimal design for individual parameter estimation in pharmacokinetics. In: M. Rowland, L. B. Sheiner, and J.-L. Steimer (eds.), Variability in Drug Therapy: Description, Estimation and Control, pp. 187–200. New York: Raven Press, 1985.
31. Laskin, J. D., Evans, R. M., Slocum, H. K., Burke, D., and Hakala, M. T. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res., 39:383–390, 1979.
32. Larson, H. J. Introduction to Probability Theory and Statistical Inference, Ed. 3. New York: John Wiley & Sons, Inc., 1982.
33. Werkheiser, W. C., Grindey, G. B., and Moran, R. G. Mathematical simulation of the interaction of drugs that inhibit deoxyribonucleic acid biosynthesis. Mol. Pharmacol., 9:320–329, 1973.
34. Fram, R. J., Robichaud, N., Bishov, S. D., and Wilson, J. M. Interactions of cis-diamminedichloroplatinum(II) with 1-θ-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res., 47:3360–3365, 1987.
35. Drewinko, B., Green, C., and Loo, T. L. Combination chemotherapy in vitro with cisdichlorodiammineplatinum(II). Cancer Treat. Rep., 60: 1619–1625, 1976.
36. Bergerat, J. P., Green, C., and Drewinko, B. Combination chemotherapy in vitro. IV. Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem. Biophys., 3: 173–180, 1979.
37. Drewinko, B., Corry, P., Bergerat, J. P., and Barlogie, B. The lethal activity of platinum compounds in combination with pyrimidine derivatives. In: A. W. Prestayko, S. T. Crooke, and S. K. Carter, (eds.), Cisplatin: Current Status and New Developments, pp. 37–55. New York: Academic Press, 1980.
38. Bergerat, J. P., Drewinko, B., Corry, P., Barlogie, B., and Ho, D. H. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-θ-D-arabi-nofuranosylcytosine. Cancer Res., 41:25–30, 1981.
39. Spriggs, D. R., Robbins, G., and Kufe, D. W. Effects of cis-diamminedichlo-roplatinum on DNA incorporation and cytotoxicity of 1-θ-D-arabinofurano-sylcytosine. Biochem. Pharmacol., 55:4297–4302, 1986.
40. Kohno, N., Ohnuma, T., Biller, H., and Holland, J. F. Effects of cisplatin (DDP) plus 5-fluorouracil (FU) vs. DDP plus cytosine arabinoside (ara-C) on head and neck (H&N) squamous multicellular tumor spheroids (MTS). Proc. Am. Assoc. Cancer Res., 28:445, 1987.
41. Kern, D. H., Morgan, C. R., and Hildebrand-Zanki, S. U. In vitro pharmacodynamics of 1-θ-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res., 48:117–121, 1988.
42. Vadi, H., and Drewinko, B. Kinetics and mechanism of the 1-θ-D-arabino-furanosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Cancer Res., 46:1105–1109, 1986.
43. Howell, S. B., and Gill, S. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro. Cancer Treat. Rep., 70:409–410, 1986.
44. Ortiz, J., and Wooley, P. V. A study of the synergistic cytotoxic effects of 5-fluorouracil and cisplatin against colon carcinoma cells using median effect analysis. Proc. Am. Assoc. Cancer Res., 28:414, 1987.
45. Swinnen, L. J., Barnes, D. M., Fisher, S. G., Albain, K. S., Fisher, R. I., and Erikson, L. C. 1-θ-D-Arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res., 49:1383–1389, 1989.
46. Woodman, R. J., Sirica, A. E., Gang, M., Kline, I., and Venditti, J. M. The enhanced therapeutic effect of os-platinum (II) diamminodichloride against LI210 leukemia when combined with cyclophosphamide of l,2-bis-(3,5-dioxopiperazine-l-yl)propane or several other antitumor agents. Chemotherapy, 18: 169–183, 1973.
47. Gale, G. R., Atkins, L. M., Meischen, S. J., Smith, A. B., and Walker, E. M., Jr. Combination chemotherapy of L1 210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. J. Natl. Cancer Inst., 57:1363–1366, 1976.
48. Gale, G. R., Atkins, L. M., Meishchen, S. J., Smith, A. B., and Walker, E. M., Jr. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents. Cancer Treat. Rep., 61: 445–450, 1977.
49. Kyriazis, A. P., Kyriazis, A. A., and Yagoda, A. Enhanced therapeutic effect of ci5-diamminedichloroplatinum(II) against nude mouse grown human pancreatic adenocarcinoma when combined with 1-θ-D-arabinofuranosylcytosine and caffeine. Cancer Res., 45:6083–6087, 1985.